Jump Therapeutics Bets on Jumping Genes for the Next Wave of Cancer Immunotherapy

In a lab at Washington University School of Medicine in St. Louis, researchers are mapping a part of the human genome that has long been dismissed as genetic junk. These so-called "jumping genes," or transposable elements, are now understood to be active in many cancers, potentially offering a new set of targets for the immune system to recognize and attack. Jump Therapeutics, a preclinical biopharmaceutical company founded in 2023, is betting its future on translating that academic insight into a new class of precision oncology therapeutics [WashU Medicine, 2026].

For founder Noah Basri, a Washington University alumnus and author on the foundational research, the company represents a direct attempt to move a promising discovery from bench to bedside [LinkedIn, 2026][WashU Medicine, 2026]. The bet is a high-stakes one, aiming to develop immunotherapies for tumors that do not typically respond to current immune-based treatments, a patient population with few good options. With fewer than ten employees and support from the St. Louis accelerator BioGenerator, Jump is operating in the quiet, high-risk zone of early-stage drug development [Synapse, May 2025][BioGenerator Ventures, 2026].

The scientific wedge in a crowded field

The company's differentiation hinges on its focus on transposable elements. These repetitive DNA sequences, which can copy and paste themselves throughout the genome, are often reactivated in cancer cells. The research from Ting Wang's lab at WashU Medicine suggests these reactivated elements produce novel proteins that could serve as tumor-specific antigens,flags that a patient's own T-cells could be trained to hunt [WashU Medicine, 2026].

This approach sits at a specific intersection of oncology. It is not chasing the same checkpoint inhibitors or CAR-T cell therapies that dominate the immuno-oncology landscape. Instead, it is looking under a different rock, seeking targets that are fundamentally native to the tumor's corrupted genome. If viable, the strategy could open a therapeutic door for cancers with low mutational burden, which are notoriously resistant to existing immunotherapies because they lack obvious neoantigens.

Building from a St. Louis foundation

Jump's origins are deeply tied to its geographic and academic roots. The company is a product of the St. Louis biotech ecosystem, having been highlighted as a top local healthtech venture and accelerated by BioGenerator [TechSTL / LinkedIn, May 2024][BioGenerator Ventures, 2026]. Basri's deep connection to the university's Department of Genetics provides a direct conduit to ongoing research, a common model for early-stage biotechs where access to intellectual property and scientific talent is critical [Crunchbase, Unknown].

The operational footprint is deliberately lean. Public databases show no disclosed drug pipeline or clinical trial data, which is consistent with a company likely conducting foundational target validation and lead optimization work [Synapse, May 2025]. The path forward will require significant capital to advance candidates through the gauntlet of preclinical testing and into human studies, a financing challenge that lies ahead.

The long road to the clinic

The ambition is clear, but the path is lined with the formidable risks inherent to novel drug discovery. The core science, while peer-reviewed and published, must now prove itself in the complex biological environment of drug development. Translating a genomic observation into a safe, effective therapy involves overcoming hurdles in drug design, delivery, and avoiding off-target effects.

Jump also enters a field with notable precedent. Its named competitors, like Transposon Therapeutics, indicate a growing, though niche, interest in this mechanism. Furthermore, the name "Leap Therapeutics" appears in search results, but refers to a separate, publicly-traded company that wound down its cancer program to pivot in a different direction,a reminder of the precariousness of early-stage biotech bets [Fierce Biotech, 2026].

For Jump to succeed, several milestones must be reached in the next 12-24 months:

• Lead candidate selection. Moving from target identification to a nominated drug candidate is the first major technical hurdle.
• Series A financing. Transitioning from accelerator support to a institutional venture round will be necessary to fund IND-enabling studies.
• Pipeline disclosure. Publicly outlining its lead program and target indication will mark its transition from a research concept to a development-stage company.

The ultimate patient population for a therapy like this would be those with solid tumors that have exhausted standard treatments, particularly cancers with low mutational burden like certain prostate, pancreatic, or ovarian cancers. For these patients, the current standard of care often involves sequential rounds of chemotherapy or targeted agents with diminishing returns and significant toxicity. The promise of a new immunotherapy modality is not just another drug, but a potential shift in the treatment paradigm,offering a chance for the immune system to engage where it previously could not. The work at Jump Therapeutics is a long-odds attempt to make that shift a reality.

Sources

1. [BioGenerator Ventures, 2026] BioGenerator | https://www.biogeneratorventures.com/
2. [Crunchbase, Unknown] Jump Therapeutics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/jump-therapeutics
3. [Fierce Biotech, 2026] Leap jumps from bio to crypto after winding down cancer program | https://www.fiercebiotech.com/biotech/leap-therapeutics-jumps-bio-crypto-after-winding-down-cancer-program
4. [LinkedIn, 2026] Noah Basri | https://linkedin.com/in/noah-basri-9927b3206
5. [Synapse, May 2025] Jump Therapeutics LLC - Drug pipelines, Patents, Clinical trials - Synapse | https://synapse.patsnap.com/organization/383baf0f6bced146fe02ca3e9f0faad8
6. [TechSTL / LinkedIn, May 2024] TechSTL’s Post | https://www.linkedin.com/feed/update/urn:li:activity:7198943610992095232/
7. [WashU Medicine, 2026] Jumping genes in cancer cells open door to new immunotherapies - WashU Medicine | https://medicine.washu.edu/news/jumping-genes-in-cancer-cells-open-door-to-new-immunotherapies